James M Cleary

25PUBLICATIONS
359CO-AUTHORS
Molecular targetsCancer diagnosisRadiation therapyPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (25)

|Jul 01, 2026
Efficacy and Tolerability of Zenocutuzumab in Advanced NRG1 Fusion-Positive Cholangiocarcinoma: Results From the eNRGy Phase II Trial.

|Feb 13, 2026
A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2.

Brandon M Huffman, Miklos Diossy, Matthew B Yurgelun

|Dec 29, 2025
MAPK Pathway Mutations Emerge in Mutant IDH1 Inhibitor-Resistant Cholangiocarcinoma and Attenuate the IFN Response.

Jinkai Wan, Hatice Duygu Saatcioglu, Haley Ellis

|Oct 29, 2025
Phase 1 clinical trial of the ataxia telangiectasia and Rad3-related inhibitor berzosertib with irinotecan in patients with advanced solid tumors (ETCTN 9938).

Liza C Villaruz, Jingxiao Jin, Hong Wang

|Sep 02, 2025
Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreatic Cancer.

Rishi Surana, Micaela Morgado, Ashwin Somasundaram

|May 12, 2025
Generation of a Biliary Tract Cancer Cell Line Atlas Identifies Molecular Subtypes and Therapeutic Targets.

Vindhya Vijay, Negin Karisani, Lei Shi

Pageof 5

Frequent Collaborators

12 joint publications

Harshabad Singh

11 joint publications

Brian M Wolpin

11 joint publications

Kimberly Perez

10 joint publications

Andrew J Aguirre